Skip to main content
Report: Smaller companies to drive immunotherapy innovation

Smaller biotech and early-stage companies will drive next-generation approaches to developing immunotherapy drugs in the coming years, according to a WuXi AppTec report. The next decade will see bigger innovations as the industry increases its understanding of the immune system, the report said, with smaller companies more aggressively bringing new therapies to market.

Full Story: